Spin-off company of the @Menendez_Lab, @CarrerasIJC & @icreacommunity, aiming to develop CAR-T candidates as a treatment for oncological diseases.
- Tweets 344
- Following 762
- Followers 1,328
- Likes 124
This week is #BrainTumourAwarenessWeek. #Glioblastoma remains one of the most aggressive and challenging primary brain tumours.
#OneChain and @VHIO are developing OC-4, a dual CAR-T therapy designed to address this complex and varable tumour.
More: lnkd.in/ePup9kf3
1
74
At #OneChain, our investigational CD1a-directed CAR-T cell therapy, OC-1, is being evaluated in the CARxALL first-in-human clinical trial for patients with relapsed or refractory T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL/T-LL).
Learn more: lnkd.in/efnZzdhk
1
2
100
In November, #OneChain will be heading to #BIOEurope 2026, 9-11th November.
Our CEO, Stefanos Theoharis, with Barbara Krebs-Pohl, our Chair of the Board, will be at this year’s meeting to connect with investors and the global biotech and pharma community.
@EBDgroup
1
63
🔝 Next week, Víctor Manuel Díaz Cortés, Head of Research at #OneChain, will be presenting at the @festofbiologics:
“From Rational CAR Design to First-in-Human Translation: Expanding CAR-T to T-ALL and Beyond.”
🗓️13/10 at 17:10
📍Cell Therapy track
Come and join the session!
54
In Vivo CAR-T therapy has many benefits, this is why at OneChain, we’ve developed a next-generation lentiviral in vivo CAR-T platform.
Learn more about it in the infographic, or visit lnkd.in/d3DWa6fP
#CART #AdvancedTherapies #Biotech
1
527
Patient recruitment is ongoing for the CARxALL clinical trial evaluating OC-1, our investigational CD1a-directed CAR-T therapy for relapsed or refractory T-ALL/T-LL.
Learn more about OC-1 and the CARxALL trial:
lnkd.in/efnZzdhk
83
Next week, we will be at #ATE26 sharing the latest data from our next-generation lentiviral in vivo CAR-T platform.
🗓️ September 8th at 3 PM
The session will be followed by a panel discussion.
See you there!
#AdvancedTherapies #CellTherapy #InVivoCART
62
T-ALL/T-LBL remains a serious disease with limited treatment options when standard therapies fail.
CAR-T cell therapies, like our investigational CD1a-directed CAR-T therapy, OC-1, can change that.
Learn more about OC-1 and the clinical trial: lnkd.in/efnZzdhk
1
1
1
132
As the pace begins to slow down in August, we’ve taken a moment to look back at everything OneChain has already achieved in 2026.
It’s been a year of scientific progress, meaningful collaborations, knowledge-sharing and growing recognition for our work in the CAR-T field. 🚀
1
91
Next week, #OneChain will be joining #GeneTherapySummit.
Our CEO Stefanos Theoharis will present “A Novel Differentiated In Vivo Lentiviral Platform”
🗓️ Thursday, July 30
⏰ 9:00 AM
Will you be in Boston? We'd love to meet you.
#InvivoCART #GeneTherapy
1
1
86
In the session, he will discuss how we are advancing in vivo CAR-T therapy at #OneChain, the rationale behind our platform design, and new preclinical proof-of-concept and benchmarking data presented for the first time.
21
On #GlioblastomaDay, we stand with everyone affected by this disease.
At #OneChain, we are advancing OC-4, a dual CAR-T cell approach for glioblastoma and committed on advancing new approaches for diseases with such high unmet need.
More information: lnkd.in/ePup9kf3
89
🔝 Last week, our CEO Stefanos Theoharis participated in the roundtable “Startups Shaping the Future of Paediatric Healthcare” organised by @i4kids_Hub (@SJDbarcelona_es).
🗣️ An interesting conversation about pediatric innovation with the participation of @aptadel and #Minoryx
1
91
🔝This week, Víctor M. Díaz Cortés, Head of Research at #OneChain, spoke at the #CGTSummit2026.
💡He presented our work on manufacturing CD1a CAR-T cells for T-ALL, addressing the prevention of tumor cell contamination on the manufacturing process, from apheresis to GMP release.
112
Last week, OneChain was proud to be part of #BIO2026 in San Diego, where our CEO, Stefanos Theoharis, met with prospective investors & strategic partners while engaging with the global pharma & biotech community at one of the industry's premier international events.
@IAmBiotech
83
It is exciting to share that OneChain’s CAR-T therapy OC-1 shows encouraging interim results ➡️ We presented new preliminary data at #EHA2026, highlighting its potential in a rare and aggressive blood cancer with limited treatment options.
More 🔗 onechaintx.com/press/onechai…
56
🎉 Today, we celebrate 6 years of #OneChain Immunotherapeutics!
✅ Since our inception, our mission has been to bring innovative cell therapies to patients facing aggressive and hard-to-treat cancers.
🔝 We have achieved significant leaps forward each year 👇
1
3
427
OneChain Immunotherapeutics will be attending #BIO2026 later this month.
Our CEO, Stefanos Theoharis, will be there 👉 if you will also be attending and would like to connect, feel free to reach out!
#Biotechnology #CellTherapy #OneChain
@IAmBiotech
41
🙌 We are pleased to welcome Carla Gaspà Vivanco to #OneChain Immunotherapeutics as a Projects Intern.
🔝 She is pursuing a double degree in Biotechnology and Business Administration at @IQSbarcelona.
At OneChain, she will support the Projects team ✅
Welcome, Carla! 👏
1
1
96